Background alzheimers Shape Background alzheimers Shape Background alzheimers Shape
Grants > Functional Interaction of APP-CTF with G-alphaS in Brain Updated On: Ene. 19, 2025
Alzheimer's Disease Research Grant

Functional Interaction of APP-CTF with G-alphaS in Brain

a headshot of Dr. Parent

Principal Investigator

Angèle Parent, PhD

University of South Florida

Tampa, FL, USA

About the Research Project

Program

Alzheimer's Disease Research

Award Type

Pilot

Award Amount

$150,000

Active Dates

July 01, 2012 - June 30, 2014

Grant ID

A2012386

Goals

Dr. Angèle Parent and her team’s research efforts focus on understanding the molecular and cellular mechanisms associated with development of Alzheimer’s disease. In this project, they are using transgenic mouse and cell culture techniques to study the function a protein that is suspected to contribute to the pathogenesis. The ultimate goal is to develop novel therapeutic strategies that are applicable to humans to fight this devastating disorder.

Summary

Dr. Angèle Parent and her team’s research efforts focus on understanding the molecular and cellular mechanisms associated with the development of Alzheimer’s disease (AD). They are using cell culture and mouse models in their research to clarify the role of a genetically engineered protein that may affect the progression of AD. Interestingly, their study identified a novel interaction of a portion of the amyloid precursor protein (APP) that resides inside the cell, termed the “intracellular domain,” with a signaling protein termed the “G-alphaS.” This molecular interaction may impact brain functions such as learning and memory. Indeed, their recent findings demonstrated that membrane accumulation of amyloid precursor protein’s intracellular domain results in inhibition of one of the important signaling cascades associated with AD pathology. Accordingly, in order to prevent or delay AD, these experiments investigate the therapeutic potential of developing a version of the amyloid precursor protein intracellular domain that remains tethered to the cell membrane.

To accomplish this they are using a virus to deliver the modified protein to mice brains. Consequences on brain functions are investigated by examining changes in neuron development and their chemistry. The viral brain administration strategy is the first step toward a comprehensive evaluation of the beneficial effect associated with brain expression of this modified protein. The ultimate goal is to develop novel therapeutic strategies applicable to humans to fight this devastating disorder. Parent and her team are greatly encouraged by their preliminary findings and confident that these investigations will yield significant advances.